Home / Resource Library / Glofitamab Monotherapy Provides Durable Responses after Fixed Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)Glofitamab Monotherapy Provides Durable Responses after Fixed Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts) ASH 2021